Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC)

Cancer Investigation

Volumn 27, Issue 8, 2009, Pages 877-884

  Chaudhry, Parvesh ^a   Srinivasan, Radhika ^b   Patel, Firuza D ^a  

^a Departments of Radiotherapy   (Netherlands)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

BRCA1; Epithelial ovarian cancer; Methylation profiling; Outcome; Platinum based chemotherapy

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PROTEIN MLH1; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CLINICAL ARTICLE; EPITHELIAL OVARIAN CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; METHYLATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; CA-125 ANTIGEN; CISPLATIN; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 70249125405     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900902849699     Document Type: Article

References (56)

1. Jemal, A.; Tiwari, R.C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E.J.; Thun, M.J.; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004, 54, 8-29.
2. Cannistra, S.A. Cancer of the ovary. N Engl J Med 2004, 351, 2519-2529.
3. Schuijer, M.; Berns, E.M. TP53 and ovarian cancer. Hum Mutat 2003, 21, 285-291.
4. Manic, S.; Gatti, L.; Carenini, N.; Fumagalli, G.; Zunino, F.; Perego, P. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003, 3 , 21-29.
5. Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 2005, 8, 131-146.
6. Jones, P.A.; Laird, P.W. Cancer epigenetics comes of age. Nat Genet 1999, 21, 163-167.
7. Herman, J.G.; Merlo, A.; Mao, L. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55 , 4525-4530.
8. Sakai, T.; Toguchid, J.; Ohtani, N.; Yandell, D.W.; Rapaport, J.M.; Dryja, T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991, 48, 880-888.
9. Herman, J.G.; Umar, A.; Polyak, K.; Graff, J.R.; Ahuja, N.; Issa, J.P.; Markowitz, S.; Willson, J.K.; Hamilton, S.R.; Kinzler, K.W.; Kane, M.F.; Kolodner, R.D.; Vogelstein, B.; Kunkel, T.A.; Baylin, S.B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998, 95, 6870-6875.
10. Fleisher, A.S.; Esteller, M.; Tamura, G.; Rashid, A.; Stine, O.C.; Yin, J.; Zou, T.T.; Abraham, J.M.; Kong, D.; Nishizuka, S.; James, S.P.; Wilson, K.T.; Herman, J.G.; Meltzer, S.J. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 2001, 20, 329-335.
11. Dobrovic, A.; Simpfendorfer, D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997, 57, 3347-3350.
12. Fink, D.; Nebel, S.; Aebi, S.; Zheng, H.; Cenni, B.; Nehme, A.; Christen, R.D.; Howell, S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996, 56, 4881-4886. (Pubitemid 26374423)
13. McCluskey, L.L.; Chen, C.; Delgadillo, E.; Felix, J.C.; Muderspach, L.I.; Dubeau, L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol 1999, 72 , 87-92.
14. Yoon, J.H.; Dammann, R.; Pfeifer, G.P. Hypermethylation of the CpG Island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001, 94, 212-217.
15. Chiang, J.W.; Karlan, B.Y.; Cass, L.; Baldwin, R.L. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gy-necol Oncol 2006, 101, 403-410.
16. Strathdee, G.; MacKean, M.J.; Illand, M.; Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999, 18, 2335-2341.
17. Strathdee, G.; Appleton, K.; Illand, M.; Millan, D.W.; Sargent, J.; Paul, J.; Brown, R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001, 158, 1121-1127.
18. Teodoridis, J.M.; Hall, J.; Marsh, S.; Kannall, H.D.; Smyth, C.; Curto, J.; Siddiqui, N.; Gabra, H.; McLeod, H.L.; Strathdee, G.; Brown, R. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005, 65, 8961-8967.
19. Liu, J.R.; Opipari, A.W.; Tan, L.; Jiang, Y.; Zhang, Y.; Tang, H.; Nunez, G. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002, 62, 924-931.
20. Anthoney, D.A.; McIlwrath, A.J.; Gallagher, W.M.; Edlin, A.R.M.; Brown, R. Microsatellite instability, apoptosis and loss of p53 function in drug resistant tumor cells. Cancer Res 1996, 56, 1374-1381.
21. Benedet, J.L.; Bender, H.; Jones III, H.; Ngan, H.Y.; Pecorelli, S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gyne-cologic Oncology. Int J Gynaecol Obstet 2000, 70, 209-262.
22. Herman, J.G.; Graff, J.R.; Myohanen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93, 9821-9826.
23. Spriggs, D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2003, 90, S39-44.
24. Maruyama, R.; Toyooka, S.; Toyooka, K.O.; Harada, K.; Virmani, A.K.; Zochbauer-Muller, S.; Farinas, A.J.; Vakar-Lopez, F.; Minna, J.D.; Sagalowsky, A.; Czerniak, B.; Gazdar, A.F. Aberrant promoter methylation profile of bladder cancer and its relationship to clini-copathological features. Cancer Res 2001, 61, 8659-8663.
25. Wiley, A.; Katsaros, D.; Chen, H.; Rigault de la Longrais, I.A.; Beeghly, A.; Puopolo, M.; Singal, R.; Zhang, Y.; Amoako, A.; Zel-terman, D.; Yu, H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006, 107, 299-308.
26. Makarla, P.B.; Saboorian, M.H.; Ashfaq, R.; Toyooka, K.O.; Toy-ooka, S.; Minna, J.D.; Gazdar, A.F.; Schorge, J.O. Promoter hy-permethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005, 11, 5365-5369.
27. Park, M.S.; De Leon, M.; Devarajan, P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002, 13, 858-865.
28. Sedletska, Y.; Giraud-Panis, M.J.; Malinge, J.M. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005, 5, 251-265.
29. Cepeda, V.; Fuertes, M.A.; Castilla, J.; Alonso, C.; Quevedo, C.; Pérez, J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007, 7, 3-18.
30. Scully, R.; Livingston, D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000, 408, 429-432.
31. Thangaraju, M.; Kaufmann, S.H.; Couch, F.J. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000, 275, 33487-33496.
32. Xu, X.; Qiao, W.; Linke, S.P.; Cao, L.; Li, W.M.; Furth, P.A.; Harris, C.C.; Deng, C.X. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001, 28, 266-271.
33. Quinn, J.E.; Kennedy, R.D.; Mullan, P.B.; Gilmore, P.M.; Carty, M.; Johnston, P.G.; Harkin, D.P. BRCA1 functions as a differential mod- ulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63, 6221-6228.
34. Sgagias, M.K.; Wagner, K.U.; Hamik, B.; Stoeger, S.; Spieker, R.; Huber, L.J.; Chodosh, L.A.; Cowan, K.H. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004, 3, 1451-1456.
35. Tassone, P.; Tagliaferri, P.; Perricelli, A.; Blotta, S.; Quaresima, B.; Martelli, M.L.; Goel, A.; Barbieri, V.; Costanzo, F.; Boland, C.R.; Venuta, S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003, 88, 1285-1291.
36. Kennedy, R.D.; Quinn, J.E.; Mullan, P.B.; Johnston, P.G.; Harkin, D.P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96, 1659-1668.
37. Fedier, A.; Steiner, R.A.; Schwarz, V.A.; Lenherr, L.; Haller, U.; Fink, D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003, 22, 1169-1173.
38. Taniguchi, T.; Tischkowitz, M.; Ameziane, N.; Hodgson, S.V.; Mathew, C.G.; Joenje, H.; Mok, S.C.; D'Andrea, A.D. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9, 568-574.
39. Catteau, A.; Harris, W.H.; Xu, C.F.; Solomon, E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999, 18, 1957-1965.
40. Esteller, M.; Silva, J.M.; Dominguez, G.; Bonilla, F.; Matias-Guiu, X.; Lerma, E.; Bussaglia, E.; Prat, J.; Harkes, I.C.; Repasky, E.A.; Gabrielson, E.; Schutte, M.; Baylin, S.B.; Herman, J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92, 564-569.
41. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hi-dalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343, 1350-1354.
42. Gerson, S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4, 296-307.
43. Brandes, A.A.; Tosoni, A.; Cavallo, G.; Reni, M.; Franceschi, E.; Bonaldi, L.; Bertorelle, R.; Gardiman, M.; Ghimenton, C.; Iuz-zolino, P.; Pession, A.; Blatt, V.; Ermani, M. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006, 24, 4746-4753.
44. Blanc, J.L.; Wager, M.; Guilhot, J.; Kusy, S.; Bataille, B.; Chantereau, T.; Lapierre, F.; Larsen, C.J.; Karayan-Tapon, L. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004, 68, 275-283.
45. Brown, R.; Hirst, G.; Gallagher, W.M.; Mcllwrath, A. J.; Van der Zee, A.; Anthoney, D.A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997, 15, 45-52.
46. Aebi, S.; Kurdi-Haidar, B.; Gordon, R.; Cenni, B.; Zheng, H.; Fink, D.; Christen, R.D.; Boland, C.R.; Koi, M.; Fishel, R.; Howell, S.B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56, 3087-3090. (Pubitemid 26199755)
47. Plumb, J.A.; Strathdee, G.; Sludden, J.; Kaye, S.B.; Brown, R. Reversal of drug resistance in human tumor xenografts by 2 -deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000, 60, 6039-6044.
48. Helleman, J.; van Staveren, I.L.; Dinjens, W.N.; van Kuijk, P.F.; Ritstier, K.; Ewing, P.C.; van der Burg, M.E.; Stoter, G.; Berns, E.M. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 2006, 6, 201.
49. Scartozzi, M.; De Nictolis, M.; Galizia, E.; Carassai, P.; Bianchi, F.; Berardi, R.; Gesuita, R.; Piga, A.; Cellerino, R.; Porfiri, E. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. Eur J Cancer 2003, 39, 1144-1149.
50. Samimi, G.; Fink, D.; Varki, N.M.; Husain, A.; Hoskins, W.J.; Al-berts, D.S.; Howell, S. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000, 6, 1415-1421.
51. Auersperg, N.; Edelson, M.I.; Mok, S.C.; Johnson, S.W.; Hamilton, T.C. The biology of ovarian cancer. Semin Oncol 1998, 25, 281-304.
52. Branch, P.; Masson, M.; Aquilina, G.; Bignami, M.; Karran, P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000, 19, 3138-3145.
53. Katsaros, D.; Cho, W.; Singal, R.; Fracchioli, S.; Rigault De La Longrais, I.A.; Arisio, R.; Massobrio, M.; Smith, M.; Zheng, W.; Glass, J.; Yu, H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 2004, 94, 685-692.
54. Esteller, M.; Corn, P.G.; Baylin, S.B.; Herman, J.G. A gene hy-permethylation profile of human cancer. Cancer Res 2001, 61, 3225-3229.
55. Baylin, S.B.; Herman, J.G. DNA hypermethylation in tumorigen-esis: epigenetics joins genetics. Trends Genet 2000, 16, 168-174.
56. Tam, K.F.; Liu, V.W.; Liu, S.S.; Tsang, P.C.; Cheung, A.N.; Yip, A.M.; Ngan, H.Y. Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol 2007, 133, 331-341.